You are here

  • Home
  • Archive
  • Volume 73, Issue 12
  • Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension

Article info

Article menu
XML
Clinical and epidemiological research
Extended report
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension

Authors

  1. Correspondence to Dr Edward Keystone, The Rebecca MacDonald Centre for Arthritis & Autoimmune Diseases, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, ON, Canada M5T 3L9; edkeystone{at}mtsinai.on.ca
View Full Text

Citation

Keystone E, Landewé R, van Vollenhoven R, et al
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
Annals of the Rheumatic Diseases 2014;73:2094-2100.

Publication history

  • Received March 27, 2013
  • Revised July 5, 2013
  • Accepted July 15, 2013
  • First published August 5, 2013.
Online issue publication 
October 30, 2014

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/